Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET. CEO Mark Erlander, PhD will deliver the presentation and host one-on-one meetings during the conference running December 10–11, 2025. Interested parties can register and access the live webcast via the company’s Events section. A webcast replay will be available after the presentation.

Cardiff Oncology (Nasdaq: CRDF) will present at the Piper Sandler 37th Annual Healthcare Conference, held December 2–4, 2025. Company management will participate in a fireside chat and 1x1 investor meetings.

Presenter: Mark Erlander, PhD, CEO. Presentation date/time: December 2, 2025 at 9:30 AM ET. Interested parties can register and watch a live webcast via the company’s Events page, and a replay will be available after the presentation.

Cardiff Oncology (Nasdaq: CRDF) reported Q3 2025 results and a business update on Nov 6, 2025. The company announced positive Phase 2 CRDF-004 data for onvansertib plus standard of care in first-line RAS-mutated metastatic colorectal cancer, citing a 19% improvement in confirmed ORR for the 30mg cohort at the July 8, 2025 data cut-off and early PFS separation favoring 30mg.

Cardiff reported $60.6 million in cash and investments as of Sept 30, 2025, net cash used in operating activities of $10.8 million in Q3 2025, and projects runway into Q1 2027. A clinical update is expected in Q1 2026.

Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two investor conferences in November 2025. CEO Mark Erlander, PhD will appear at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on 11/11/2025 at 9:30 AM ET for a fireside chat and 1x1 meetings, and at the Stifel 2025 Healthcare Conference on 11/12/2025 at 9:20 AM ET for a corporate presentation and 1x1 meetings.

Interested parties can register and access live webcasts via the company’s Events page; replay will be available after each presentation.

Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two virtual investor conferences on October 9, 2025. A Piper Sandler Virtual Oncology Symposium fireside chat will feature Mark Erlander, PhD (CEO), James Levine (CFO) and Roger Sidhu, MD (CMO) at 1:00 PM ET. A Noble Capital Markets Emerging Growth Virtual Equity Conference fireside chat will feature Mark Erlander at 2:00 PM ET.

Attendance instructions: contact Piper Sandler for access; Noble registration is free. A webcast replay will be posted within 48 hours in the Events section of Cardiff Oncology’s website.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in three major investor conferences in September 2025.

The company will attend the Wells Fargo Healthcare Conference (09/05), the Morgan Stanley Global Healthcare Conference (09/08), and the H.C. Wainwright Global Investment Conference (09/09). CEO Mark Erlander will present a fireside chat at the H.C. Wainwright conference at 10:30 AM ET, which will be available via webcast on the company's website.

Cardiff Oncology (Nasdaq: CRDF) announced positive data from its Phase 2 clinical trial evaluating onvansertib combined with standard-of-care (SoC) for first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a 49% confirmed objective response rate (ORR) in the 30mg onvansertib arm versus 30% in the control arm.

Key highlights include:

• Dose-dependent response across all endpoints including ORR, early tumor shrinkage, and depth of response
• Early PFS data showing favorable trend for 30mg onvansertib dose
• Well-tolerated safety profile with neutropenia as the most common treatment-emergent adverse event

The company plans to engage with FDA regarding the registrational CRDF-005 trial and expects to provide a program update by Q1 2026.

Cardiff Oncology (Nasdaq: CRDF) announced Q2 2025 financial results and significant clinical progress. The company completed enrollment in its randomized Phase 2 CRDF-004 trial for onvansertib plus standard of care in first-line RAS-mutated metastatic colorectal cancer. Key highlights include the appointment of Dr. Roger Sidhu as Chief Medical Officer and positive data from a Phase 1b trial showing 40% objective response rate for onvansertib with paclitaxel in metastatic triple negative breast cancer.

Financially, Cardiff reported $71.0 million in cash and investments as of June 30, 2025, with a projected runway into Q1 2027. Q2 operating expenses increased to $14.9 million, up from $12.7 million year-over-year, primarily due to clinical trial costs and personnel expenses. The company also secured a new USPTO patent for onvansertib treatment in mCRC, extending protection until 2043.

Cardiff Oncology (NASDAQ: CRDF) has appointed Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar who will transition to an advisory role. Dr. Sidhu brings over 20 years of oncology leadership experience, including significant expertise in mCRC clinical trials and RAS biology. He previously served as CMO and acting CEO at Treadwell Therapeutics and held key positions at Amgen, where he led Phase 3 trials for panitumumab. The company also announced a conference call scheduled for July 29, 2025, at 4:30 PM ET to share additional clinical data from its randomized Phase 2 CRDF-004 trial, which evaluates onvansertib plus standard of care for first-line RAS-mutated metastatic colorectal cancer treatment. As part of his compensation package, Dr. Sidhu received an inducement grant of options to purchase 600,000 shares at $3.86 per share, vesting over four years.